Harpsoe, K. | Search bioRxiv

bioRxiv2021

Molecular determinants underlying DS2 activity at δ-containing GABAA receptors

Delta selective compound 2 (DS2) is one of the most widely used tools to study selective actions mediated by {delta} subunit-containing GABAA receptors. DS2 was discovered over 10 years ago, but despite great efforts, the precise molecular site of action has remained elusive. Using a combination of computational modeling, site-directed mutagenesis and cell-based pharmacological assays, we probed three potential binding sites for DS2 and analogs at 4{beta}1{delta} receptors: an 4(+){delta}(-) interface site in the extracellular domain (ECD), equivalent to the diazepam binding site in {beta}{gamma}2 receptors, and two sites in the transmembrane domain (TMD); one in the 4(+){beta}1(-) and one in the 4(-){beta}1(+) interface, with the 4(-){beta}1(+) site corresponding to the binding site for etomidate and a recently disclosed low-affinity binding site for diazepam. We show that mutations in the ECD site did not abrogate DS2 modulation. However, mutations in the TMD 4(+){beta}1(-) interface, either 4(S303L) of the 4(+)-side or {beta}1(I289Q) of the {beta}1(-)-side, convincingly disrupted the positive allosteric modulation by DS2. This was consistently demonstrated both in an assay measuring membrane potential changes and by whole-cell patchclamp electrophysiology and rationalized by docking studies. Importantly, general sensitivity to modulators was not compromised in the mutated receptors. This study sheds important light on the long-sought molecular recognition site for DS2, refutes the misconception that the selectivity of DS2 for {delta}-containing receptors is caused by a direct interaction with the {delta}-subunit, and instead points towards a functional selectivity of DS2 and its analogs via a surprisingly well-conserved binding pocket in the TMD. Significance statement{delta}-Containing GABAA receptors represent potential drug targets for the treatment of several neurological conditions with aberrant tonic inhibition. Yet, no drugs are currently in clinical use. With the identification of the molecular determinants responsible for positive modulation by the know compound DS2, the ground is laid for design of ligands that selectively target {delta}-containing GABAA receptor subtypes, for better understanding of tonic inhibition, and, ultimately, for rational development of novel drugs.

pharmacology and toxicology↗

bioRxiv2020

A genetically encoded red fluorescence dopamine biosensor enables dual imaging of dopamine and norepinephrine

Dopamine (DA) and norepinephrine (NE) are pivotal neuromodulators that regulate a broad range of brain functions, often in concert. Despite their physiological importance, untangling the relationship between DA and NE in finely controlling output functions is currently challenging, primarily due to a lack of techniques to visualize spatiotemporal dynamics with sufficiently high selectivity. Although genetically encoded fluorescent biosensors have been developed to detect DA, their poor selectivity prevents distinguishing DA from NE. Here, we report the development of a red fluorescent genetically encoded GPCR (G protein-coupled receptor)-activation reporter for DA termed R-GenGAR-DA. More specifically, a circular permutated red fluorescent protein (cpmApple) was inserted into the third intracellular loop of human DA receptor D1 (DRD1) followed by the screening of mutants within the linkers between DRD1 and cpmApple. We developed two variants: R-GenGAR-DA1.1, which brightened following DA stimulation, and R-GenGAR-DA1.2, which dimmed. R-GenGAR-DA1.2 demonstrated reasonable dynamic range ({Delta}F/F0 = -50%) and DA affinity (EC50 = 0.7 {micro}M) as well as the highest selectivity for DA over NE (143-fold) amongst available DA biosensors. Due to its high selectivity, R-GenGAR-DA1.2 allowed dual-color fluorescence live imaging for monitoring DA and NE, combined with the existing green-NE biosensor GRABNE1m, which has high selectivity for NE over DA (>350-fold) in HeLa cells and hippocampal neurons grown from primary culture. By enabling precise measurement of DA, as well as simultaneous visualization of DA and NE, the red-DA biosensor R-GenGAR-DA1.2 is promising in advancing our understanding of the interplay between DA and NE in organizing key brain functions. Significance StatementThe neuromodulators dopamine and norepinephrine modulate a broad range of brain functions, often in concert. One current challenge is to measure dopamine and norepinephrine dynamics simultaneously with high spatial and temporal resolution. We therefore developed a red-dopamine biosensor that has 143-fold higher selectivity for dopamine over norepinephrine. Taking advantage of its high selectivity for dopamine over norepinephrine, this red-dopamine biosensor allowed dual-color fluorescence live imaging for monitoring dopamine and norepinephrine in both HeLa cells and hippocampal neurons in vitro combined with the existing green-norepinephrine biosensor that has 350-fold selectivity for norepinephrine over dopamine. Thus, this approach can provide new opportunities to advance our understanding of high spatial and temporal dynamics of dopamine and norepinephrine in normal and abnormal brain functions.

cell biology↗